← Leaderboards
Anna C Pavlick
New York University School Of Medicine
$546,957
Attributed
$546,957
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $541.7K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$546,957 · 3
By mechanism
P30$541,684 · 1
M01$5,273 · 2
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Howard S Hochster$9,390,994
- Mark Joseph Mulligan$87,307,980
- Michele Pagano$20,677,630
- Benjamin G. Neel$33,134,772
- Jing Wang$11,467,417
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationChemopreventionFemaleTamoxifenPostmenopauseBreast NeoplasmsUterus NeoplasmsEstrogen InhibitorWomen'S HealthPatient Oriented ResearchClinical TrialsCancer Clinical TrialClinical ProtocolsClinical ManagementCancer Center Support GrantAwarenessEnsureClinical DataDisease ManagementData ManagementClinical Cancer Center
Grant awards (6)
Clinical Protocol and Data Management$541,684
P30 · FY2019 · CA · contact PI
NSABP P-2: STUDY OF TAMOXIFEN AND RALOXIFENE( STAR) TO PREVENT BREAST CANCER$955
M01 · FY2005 · RR
Thalidomide and Dacarbazine for Metastatic Melanoma$3,302
M01 · FY2004 · RR
NSABP P-2: Study of Tamoxifen and Raloxifene( STAR) to Prevent Breast Cancer$1,016
M01 · FY2004 · RR
NYU 98 76--TAMOXIFEN AND RALOXIFENE FOR PREVENTION OF BREAST CANCER$0
M01 · FY2000 · RR
NYU 98 76--TAMOXIFEN AND RALOXIFENE FOR PREVENTION OF BREAST CANCER$0
M01 · FY2000 · RR